NA-ACCORD COVID-19 Supplment
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3U01AI069918-14S1
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$5,429,240Funder
National Institutes of Health (NIH)Principal Investigator
PendingResearch Location
United States of AmericaLead Research Institution
JOHNS HOPKINS UNIVERSITYResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Individuals with multimorbidity
Occupations of Interest
Unspecified
Abstract
The North American - AIDS Cohort Collaboration on Research and Design (NA-ACCORD), the Region 1representative of the IeDEA network, aims to describe the HIV epidemic in the US and Canada and answerquestions important to the contemporary care and health of persons with HIV. We propose to leverage theresearch infrastructure of the NA-ACCORD to support our infectious disease epidemiologists and clinical co-investigators as they pivot to answer urgent COVID-19 questions in people with (PWH) and without (PWOH)HIV among existing and new cohorts. By supporting a) 2 existing cohorts and the establishment of 3longitudinal COVID-19 clinical cohorts curated from available electronic health record (EHR data), b) datamanagement and analytic expertise specific to the profound health impacts of infectious disease, c) a library ofCOVID-19 data collection tools, and d) the sharing of EHR-based algorithms for COVID-19, we will acceleratethe answers to the following urgent COVID-19 questions: 1) Who is getting tested for SARS-Cov-2, whatproportion are positive, and what are predictors of a positive test? 2) What are risk factors for hospitalizationafter testing positive for SARS-Cov-2? 3) Do angiotensin-converting enzymes (ACE) inhibitors or angiotensin IItype-I receptor blockers (ARBs) increase the risk of severe COVID-19 illness? 4) What is the impact of thehealthcare system's adaptation to the surge of people becoming ill with COVID-19 on the all-cause mortalityamong those with HIV (a chronic condition that requires routine care)? Infectious disease epidemiologists andclinicians are needed to answer urgent COVID-19 questions. The NA-ACCORD will support co-investigatorsand their analytic teams, provide the infrastructure to share information, and examine the heterogeneity inanswering these COVID-19 questions investigated expeditiously in 5 existing and new cohorts.